Regeneron to present new Ordspono, Lynozyfic and hematology pipeline data at ASH 2026

Regeneron Pharmaceuticals will present new and updated clinical data across 14 abstracts at the 2026 American Society of Hematology Annual Meeting.

The presentations will cover malignant and classical hematology programmes, including lymphoma, multiple myeloma, systemic light chain amyloidosis and paroxysmal nocturnal haemoglobinuria.

The meeting will take place from December 12 to 15 in New Orleans.

Among the key presentations will be the primary analysis of Ordspono in patients with relapsed or refractory marginal zone lymphoma from the ELM-2 study.

Regeneron described the dataset as potentially registrational and said it could support development of the CD20xCD3 bispecific antibody in a patient population with limited treatment options.

Ordspono, also known as odronextamab, is already approved in the European Union for certain patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma after at least two previous systemic therapies.

Its use in marginal zone lymphoma remains investigational.

Regeneron will also present longer-term findings for Lynozyfic in relapsed or refractory systemic light chain amyloidosis.

The Phase I/II LINKER-AL2 data will include updated clinical findings and biomarker analyses examining plasma cell depletion and T-cell activation.

Lynozyfic, or linvoseltamab, is a BCMAxCD3 bispecific antibody.

The company will also report a post-hoc analysis from the Phase II LINKER-MM1 study examining treatment-free remission in patients with relapsed or refractory multiple myeloma.

Additional Lynozyfic presentations include minimal residual disease and durability results from the investigator-led IMMUNOPLANT study in newly diagnosed multiple myeloma.

A Phase III study comparing fixed-duration linvoseltamab with daratumumab in high-risk smouldering multiple myeloma will also be included in the ASH programme.

Regeneron’s classical hematology programme will feature analyses of cemdisiran combined with pozelimab in paroxysmal nocturnal haemoglobinuria.

The company will present data examining lactate dehydrogenase normalisation and transfusion avoidance with the combination compared with ravulizumab in a Phase III study.

Cemdisiran and pozelimab remain investigational.

Regeneron will also present early clinical data from ALN-CFB, an investigational siRNA targeting hepatic complement factor B in patients with persistent anaemia associated with PNH.

Other pipeline presentations will include a GPRC5D×CD28 costimulatory bispecific antibody in combination with a BCMA×CD3 T-cell engager, REGN7257 in severe aplastic anaemia and REGN7999 in a preclinical beta-thalassaemia model.

L. Andres Sirulnik, MD, PhD, Senior Vice President and Head of Regeneron’s Hematology Clinical Development Unit, said the presentations reflect the company’s strategy of extending its bispecific antibody programmes into additional blood cancers and disorders while developing new therapeutic approaches.

The full clinical results from the highlighted studies are expected to be presented during the ASH meeting in December.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy